Data From TNFerade TM Esophageal Cancer Study Presented At 2010 ASCO Gastrointestinal Cancer Symposium
GenVec, Inc. (Nasdaq: GNVC) announced that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010. The poster, titled, "Long term survival analysis of multicenter clinical trial using endoscopy (END) and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of antitumor agent (TNFerade Biologic (TNF)) in patients with locally advanced esophageal cancer, " reports on updated efficacy and survival data. In the 24 patients receiving TNFerade in combination with chemoradiation, the median survival was 47.
IsoRay, Inc. (AMEX:ISR), announced that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world's first Cesium-131(Cs-131) implant for the treatment of colorectal cancer. This implant was performed on a 38-year-old patient with locally recurrent colon cancer who underwent surgical resection of the tumor as a part of the treatment. The patient has a history of multiple prior surgeries and chemotherapy for colorectal cancer. Dr. Parashar stated, "The patient tolerated the procedure well and had no evidence of cancer recurrence or any side effects that can be attributed to the Cesium-131 seed implant at the last follow-up visit.
Researchers at the University of Southern California (USC) have, for the first time, identified specific genetic variations that predict clinical outcomes in patients with gastric (stomach) cancer. Genetic variations within the CD44 gene may be responsible for early tumor recurrence and metastasis, said Thomas Winder, M.D., a postdoctoral research fellow at the Keck School of Medicine of USC and the USC Norris Comprehensive Cancer Center, and the lead author on the study. Patients with the genetic variations experience cancer recurrence more than three times sooner than patients without the variations, the investigators found. Winder presented the findings during a news briefing at the American Society of Clinical Oncology (ASCO) 2010 Gastrointestinal Cancers Symposium.
Calcium may not come to mind when you think of tasty foods, but in a study appearing in the January 8 issue of JBC, Japanese researchers have provided the first demonstration that calcium channels on the tongue are the targets of compounds that can enhance taste. In addition to molecules that directly trigger specific taste buds (salty, sweet etc.), there are other substances which have no flavor of their own but can enhance the flavors they are paired with (known as kokumi taste in Japanese cuisine). Exploiting this enhancement could have practical uses in food modulation; for example, creating healthy foods that contain minimal sugar or salt but still elicit strong taste.
New Avastin R bevacizumab Data Confirm Overall Survival Of Beyond Two Years In Patients With Metastatic Bowel Cancer
Welwyn Garden City, 21st January 2010. New data from two large studies presented at the ASCO GI* congress in Orlando, USA, shows rates of tumour shrinkage, and median overall survival beyond two years when bevacizumab is combined with the most common chemotherapy regimens.1, 2 This new data further validates the access to bevacizumab as a standard of care for metastatic bowel cancer patients throughout most of Europe for the last five years. Unfortunately patients in the UK still do not have universal access to this potentially life extending treatment. NICE issued preliminary guidance at the end of November 2009 that would deny patients access to bevacizumab for the treatment of metastatic bowel cancer on the NHS, but a final decision is expected shortly following NICE's Committee meeting next week.
New research on the treatment of gastrointestinal cancers was released today in advance of the seventh annual Gastrointestinal Cancers Symposium, being held January 22-24, 2010, at the Orlando World Center Marriott. Four significant studies were highlighted today in a presscast (press briefing via live webcast): - Simple blood test detects colorectal cancer and colorectal adenomas: A new test for blood levels of the CD24 protein is more than 90 percent sensitive and specific for detecting colorectal cancer, and more than 80 percent accurate at detecting potential precancers, called adenomas. These findings may prove useful for identifying patients who would benefit most from colonoscopy.